The mechanism of solifenacin release from a pH-responsive ion-complex oral suspension in the fasted upper gastrointestinal lumen.
Bile salts
Biorelevant gastrointestinal transfer system (BioGIT)
Flow-through cell apparatus (USP Apparatus 4)
Ion-exchange resin
Paddle apparatus (USP Apparatus 2)
Polacrilin potassium
Taste-masking
Journal
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
ISSN: 1879-0720
Titre abrégé: Eur J Pharm Sci
Pays: Netherlands
ID NLM: 9317982
Informations de publication
Date de publication:
15 Jan 2020
15 Jan 2020
Historique:
received:
14
08
2019
revised:
09
10
2019
accepted:
10
10
2019
pubmed:
2
11
2019
medline:
2
6
2020
entrez:
1
11
2019
Statut:
ppublish
Résumé
The main objective of this study was to investigate the mechanism of solifenacin release from a pH-responsive ion-complex oral resinate suspension under conditions simulating the environment in the upper gastrointestinal lumen. A secondary objective was to propose an appropriate in vitro methodology for evaluating the quality of orally administered solifenacin suspensions. The mechanism of solifenacin release from polacrilin potassium resin (Amberlite® IRP88) was investigated using biorelevant media and compendial setups (USP Apparatus 2 and USP Apparatus 4) and using newer, recently validated in vitro methodologies [biorelevant gastrointestinal transfer (BioGIT) system]. We evaluated the impact of particle size and concentration of the resin; thickener concentration (carbomer homopolymer, type B); and the impact of pH, cationic strength, agitation intensity and level of simulation of contents in the upper gastrointestinal lumen. Data suggested that solifenacin release from the resinate was determined by the resin particle size, the medium pH, cationic strength (when the conditions in the upper small intestine are simulated) and the level of simulation of contents in the upper small intestine. The interaction of solifenacin with taurocholic acid/lecithin aggregates was significant, but unlikely to affect the degree of solifenacin absorption, as a BCS Class I compound. Under acidic conditions, solifenacin was dissociated and released from the pH-responsive resin rapidly. Under conditions simulating the contents of the upper small intestine, solifenacin was replaced by cations from the testing media and diffused through the resin matrix. All three in vitro systems with or without a pH gradient are useful in distinguishing solifenacin release characteristics from resinate suspensions with different particle sizes. Because of this drug release mechanism, USP Apparatus 2 with fixed pH media demonstrated equivalent or slightly higher discriminative sensitivity than the other setups and appears to be appropriate for product quality control.
Identifiants
pubmed: 31669386
pii: S0928-0987(19)30380-X
doi: 10.1016/j.ejps.2019.105107
pii:
doi:
Substances chimiques
Suspensions
0
Solifenacin Succinate
KKA5DLD701
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
105107Informations de copyright
Copyright © 2019 Elsevier B.V. All rights reserved.